These are the stocks that are passing at least three of my five filters, for the week of October 5. It is an unusual week in that the markets, the Congress, and the Fed are all providing lots of entertainment.
Symbol | Top Ranked | Zacks | PEG | SuppDem | VL | IBD Stock checkup |
FLIR | 1 | 1 | 1 | 1 | A+ | |
AFAM | 1 | 1 | 1 | A+ | ||
AMED | 1 | 1 | 1 | A+ | ||
BWLD | 1 | 1 | 1 | A+ | ||
CELG | 1 | 1 | 1 | A+ | ||
EZPW | 1 | 1 | 1 | A+ | ||
MANT | 1 | 1 | 1 | A+ | ||
OSIP | 1 | 1 | 1 | A+ | ||
PRGO | 1 | 1 | 1 | A+ | ||
ARO | 1 | 1 | 1 | A | ||
URBN | 1 | 1 | 1 | A |
JOY and MON are off the core list. AMED, MANT, and OSIP are new. Amedisys provides home health and hospice services. ManTech provides technologies and solutions for national security programs in the United States and internationally. (Any Alias fans out there?) OSI Pharmaceuticals discovers, develops, and commercializes molecular targeted therapies for oncology, diabetes, and obesity in the United States and internationally. (All growing problems here.)
Core list (with n of 10 weeks passing):
Symbol | Passing weeks | Earnings |
ARO | 10 | Earn 3-Dec |
FLIR | 10 | Earn 23-Oct |
WAB | 9 | |
EZPW | 9 | |
AXYS | 8 | |
CELG | 7 | Earn 23-Oct |
CF | 6 | |
URBN | 6 | Earn 13-Nov |
ACI | 5 | |
ESV | 5 | Earn 23-Oct |
HAL | 5 | Earn 20-Oct |
NOV | 5 | Earn 23-Oct |
RIMM | 5 | Earn 18-Dec |
XLNX | 5 | Earn 15-Oct |
BUCY | 5 | Earn 23-Oct |
FSLR | 5 | |
SOHU | 5 | |
VMI | 5 | Earn 15-Oct |
AMED | 5 | Earn 28-Oct |
MANT | 5 | |
OSIP | 5 | |
moving down this week | |
moving up this week | |
new this week |
Mr. Market is quite beside himself with a deep blue funk. Even an interest rate cut and the passing of the TARP brings no cheer.
My advice? Run for the hills. Get out of long positions, or balance your longs with carefully chosen shorts. Get out of debt. Grow food for yourself. Yes, the market might still go up 400 points in the next day or three, but it will undoubtedly turn out to be a sucker's rally. Enjoy your trading this week. Remeber that cash is a position, too.
No comments:
Post a Comment